Literature DB >> 27162471

Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.

Martin Paspe Cruz.   

Abstract

Entities:  

Year:  2016        PMID: 27162471      PMCID: PMC4849339     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


× No keyword cloud information.
  11 in total

Review 1.  Lenalidomide - current understanding of mechanistic properties.

Authors:  Nishant Tageja
Journal:  Anticancer Agents Med Chem       Date:  2011-03       Impact factor: 2.505

2.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

Review 3.  Lenalidomide in the treatment of multiple myeloma: a review.

Authors:  X Armoiry; G Aulagner; T Facon
Journal:  J Clin Pharm Ther       Date:  2008-06       Impact factor: 2.512

4.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Authors:  Donna M Weber; Christine Chen; Ruben Niesvizky; Michael Wang; Andrew Belch; Edward A Stadtmauer; David Siegel; Ivan Borrello; S Vincent Rajkumar; Asher Alban Chanan-Khan; Sagar Lonial; Zhinuan Yu; John Patin; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

5.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

Review 6.  Multiple myeloma.

Authors:  Marc S Raab; Klaus Podar; Iris Breitkreutz; Paul G Richardson; Kenneth C Anderson
Journal:  Lancet       Date:  2009-06-21       Impact factor: 79.321

7.  Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

Authors:  Heinz Ludwig; Brian G M Durie; Vanessa Bolejack; Ingemar Turesson; Robert A Kyle; Joan Blade; Rafael Fonseca; Meletios Dimopoulos; Kazuyuki Shimizu; Jesus San Miguel; Jan Westin; Jean-Luc Harousseau; Meral Beksac; Mario Boccadoro; Antonio Palumbo; Bart Barlogie; Chaim Shustik; Michele Cavo; Philip R Greipp; Douglas Joshua; Michel Attal; Pieter Sonneveld; John Crowley
Journal:  Blood       Date:  2008-02-11       Impact factor: 22.113

8.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

9.  Problems monitoring response in multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

Review 10.  Mechanism of action of lenalidomide in hematological malignancies.

Authors:  Venumadhav Kotla; Swati Goel; Sangeeta Nischal; Christoph Heuck; Kumar Vivek; Bhaskar Das; Amit Verma
Journal:  J Hematol Oncol       Date:  2009-08-12       Impact factor: 17.388

View more
  2 in total

1.  High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system.

Authors:  Christopher Heim; Marcus D Hartmann
Journal:  Acta Crystallogr D Struct Biol       Date:  2022-02-18       Impact factor: 7.652

2.  Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma.

Authors:  Deborah Osafehinti; Kaveh Zivari
Journal:  Case Rep Hematol       Date:  2019-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.